Fig. 7
In vivo crenezumab-mediated target engagement correlates between the periphery and brain. Significant elevations in plasma Aβ40 (a) (ANOVA: F4,19 = 23.43, p < 0.0001) and Aβ42 (b) (ANOVA: F4,19 = 12.08, p < 0.0001) were found 7 days after crenezumab treatment. A significant correlation was observed between the elevations in plasma Aβ40 (c) (R2 = 0.08, p < 0.001) and Aβ42 (d) (R2 = 0.67, p < 0.001) and crenezumab mossy fiber binding (see Fig. 4) by linear regression. N = 5/group. ANOVA followed by Tukey’s multiple comparison test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 as indicated or to control IgG